Welcome to Skilled in the Art. I’m Law.com IP reporter Scott Graham. If imitation is the sincerest form of flattery, then the drug-pricing antitrust class action against Gilead Sciences must look like a winner. Today I have news of the first (that I know of) copycat class action on the heels of last week’s Staley v. Gilead Sciences Inc.bombshell. Plus, check out who’s plugging (sort of) Simon Tam’s insider account of his Supreme Court battle with the PTO. And the champagne corks should be popping tomorrow in Waco as TC Heartland marks its two-year anniversary. Do not miss: Late last night, Judge Koh handed a sweeping win to the Federal Trade Commission in its antitrust battle with Qualcomm. As always, you can email meyour thoughts and follow me on Twitter.


 

 

Gilead Drug Pricing Suit Draws a Copycat

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]